Hermetica Superfood Encyclopedia
The Short Answer
Zeaxanthin from Dunaliella salina, predominantly isolated as zeaxanthin heneicosylate, exerts cardioprotective and neuroprotective effects by restoring antioxidant enzyme activity (superoxide dismutase), suppressing NF-κB-mediated inflammatory signaling, and upregulating cardiac glucose transporter-4 (GLUT4) expression. In preclinical rat models of D-galactose-induced cardiac dysfunction, oral zeaxanthin heneicosylate at 250 μg/kg for 28 days normalized ECG parameters, reduced serum cardiac injury markers (CK-MB, LDH), cut NF-κB expression by approximately 18%, and restored SOD activity toward baseline values.
CategoryExtract
GroupMarine-Derived
Evidence LevelPreliminary
Primary Keywordzeaxanthin Dunaliella salina benefits
Zeaxanthin (Dunaliella salina) — botanical close-up
Health Benefits
**Cardioprotective Activity**
Zeaxanthin heneicosylate (250 μg/kg orally) normalized ST-segment height, T-wave morphology, and PR interval in D-galactose-induced cardiac dysfunction rat models, while reducing serum homocysteine, CK-MB, and LDH, indicating mitigation of cardiomyocyte injury and electrical remodeling.
**Antioxidant Enzyme Restoration**: Treatment with D
salina-derived zeaxanthin significantly restored myocardial superoxide dismutase (SOD) activity—raised by approximately 74% in diseased controls—returning levels to near-normal ranges, thereby reducing oxidative damage to cardiac tissue.
**Anti-inflammatory Signaling Suppression**
Zeaxanthin modulates NF-κB transcription factor activity (reducing expression by ~18%), along with downstream targets inducible nitric oxide synthase (iNOS) and interleukin-6 (IL-6), collectively dampening the chronic low-grade inflammatory state associated with aging and cardiac dysfunction.
**Neuroprotective and Cognitive Support**: Oral D
salina biomass (250 mg/kg) and isolated zeaxanthin (250 μg/kg) markedly reduced escape latency time in Morris water maze testing, lowered brain amyloid-beta (Aβ) deposition, and decreased neuroinflammatory markers IL-1β and iNOS in D-galactose-induced dementia rat models.
**Neurotransmitter Modulation**: D
salina-derived fractions elevated brain serotonin (5-HT), norepinephrine (NE), and dopamine (DOP) concentrations in aging rat models, suggesting a role in maintaining monoaminergic neurotransmission relevant to mood, cognition, and age-related neurodegeneration.
**Hepatorenal Protective Effects**
At 250 μg/kg in D-galactose-treated rats exhibiting 1.2–2.5-fold elevations in ALT, AST, serum urea, and creatinine, zeaxanthin heneicosylate restored these biomarkers to normal ranges, indicating secondary organ protection against oxidative and inflammatory insult.
**Glucose Metabolism Enhancement**
Zeaxanthin treatment upregulated cardiac GLUT4 (glucose transporter-4) expression in aging models, improving glucose uptake in cardiomyocytes and potentially addressing the metabolic impairment that contributes to age-related cardiac dysfunction.
Origin & History
Natural habitat
Dunaliella salina is a halophilic unicellular green microalga thriving in hypersaline environments such as salt lakes, coastal lagoons, and inland saltwater bodies worldwide, including the Dead Sea, Australian salt lakes, and the Rann of Kutch in India. It accumulates exceptionally high concentrations of carotenoids—particularly β-carotene and zeaxanthin—as a photoprotective response to extreme salinity (up to 100 g/L NaCl), high light intensity, and nutrient limitation. Commercial and research cultivation is conducted in open raceway ponds or closed photobioreactors using defined media such as BG11 supplemented with high NaCl concentrations, with biomass harvested during peak carotenoid accumulation phases.
“Dunaliella salina has no documented history of traditional human medicinal use in classical pharmacopeias or ethnobotanical records, as its identification and study as a distinct microalgal species did not occur until the 19th and 20th centuries. The alga's contemporary relevance stems from industrial and biotechnological interest beginning in the 1960s–1980s, primarily as one of the richest natural sources of β-carotene for food coloring, cosmetic, and nutraceutical industries, with large-scale production facilities established in Australia, Israel, and China. Zeaxanthin specifically as a primary therapeutic focus from D. salina is a more recent research development, emerging alongside growing scientific interest in macular degeneration prevention and anti-aging medicine during the 2000s and 2010s. The preparation of purified zeaxanthin heneicosylate represents a modern pharmaceutical extraction paradigm with no traditional preparation analog, relying on controlled photobioreactor cultivation and high-performance chromatographic isolation techniques.”Traditional Medicine
Scientific Research
The evidence base for zeaxanthin from D. salina is entirely preclinical as of the available literature, comprising rat models of D-galactose-induced accelerated aging, cardiac dysfunction, and dementia, with no published human clinical trials identified. Study designs involve small group sizes (estimated 4–6 animals per treatment arm, typical for these model types) and short intervention windows of 2–8 weeks, limiting statistical power and translational certainty. Quantified outcomes include normalized ECG parameters, ~18% reduction in NF-κB, ~74% SOD rise from diseased baselines, and significant reductions in Aβ and monoamine neurotransmitter restoration, representing large effect sizes within the controlled rodent models. While these preclinical findings are mechanistically coherent and internally consistent across multiple studies, the absence of human pharmacokinetic data, dose-ranging trials, or randomized controlled trials means the clinical relevance remains speculative, and caution is warranted in extrapolating these results to human supplementation.
Preparation & Dosage
Traditional preparation
**Biomass Powder (whole D. salina)**
250 mg/kg in rat studies; human equivalent dose not established; typically provided as dried or spray-dried algal biomass containing 6–7
Used at .4 mg/L total carotenoids at harvest.
**Carotenoid Fraction (hexane/ethyl acetate extract)**
30 mg/kg in rat models; partially purified fraction retaining zeaxanthin, β-carotene, and lutein; standardization percentage not formally defined in current studies
Used at .
**Isolated Zeaxanthin Heneicosylate**
The most pharmacologically characterized form; used at 250 μg/kg orally in rat cardiac and cognitive studies; an amorphous orange compound with UV λmax at 423, 446, and 475 nm; purified via silica gel column chromatography from hexane algal extracts.
**Polar Fraction**
30 mg/kg in rat dementia studies; contains polar carotenoid derivatives and possible polar lipids; preparation involves partitioning of crude algal extract
Used at .
**Human Equivalent Dose Estimate**
Applying body surface area scaling (rat-to-human factor ~6.2), 250 μg/kg in rats corresponds approximately to 40 μg/kg in humans (~2,800 μg/70 kg adult), but this extrapolation is unvalidated and no human dosing standards have been established.
**Timing**
In rat studies, daily oral administration for 28 days (cardiac) or 14 days (cognitive) was effective; optimal timing relative to meals in humans is unknown.
**Aquaculture Feed Inclusion**
Optimal D. salina inclusion for zeaxanthin tissue deposition in shrimp is 0.34–1.53% of feed dry weight, with dose-dependent deposition up to 2.00%.
Nutritional Profile
D. salina biomass is characterized by a high carotenoid content of 6.08–7.41 mg/L of culture (total carotenoids), with zeaxanthin present as the principal esterified xanthophyll (zeaxanthin heneicosylate) alongside β-carotene (the dominant carotenoid at up to 8–14% dry weight under stress conditions), lutein, and astaxanthin. The alga also contains glycerol (as an osmolyte, up to 40% dry weight under hypersaline stress), proteins (10–30% dry weight depending on growth phase), lipids including polar and neutral lipids enriched in polyunsaturated fatty acids, and photosynthetic pigments (chlorophylls a and b). Zeaxanthin bioavailability from D. salina is enhanced by its esterified form (zeaxanthin heneicosylate), which may improve stability during gastrointestinal transit, and by the lipid matrix of the algal biomass that facilitates micellarization; dose-dependent tissue deposition observed in aquaculture models confirms absorption, though human-specific bioavailability data are absent. Micronutrients include trace minerals (iron, zinc, magnesium) and B-vitamins inherent to the algal cell, though concentrations vary significantly with cultivation conditions and are not standardized for pharmaceutical preparations.
How It Works
Mechanism of Action
Zeaxanthin heneicosylate from D. salina acts through multiple convergent molecular mechanisms: it directly quenches reactive oxygen species (ROS) via its conjugated polyene chromophore and activates endogenous antioxidant pathways (SOD restoration), while inhibiting NF-κB nuclear translocation to reduce transcription of pro-inflammatory cytokines including IL-6 and iNOS. At the receptor level, zeaxanthin exhibits high-affinity binding to retinoid acid receptor alpha (RAR-α; inferred from molecular docking studies), upregulating RAR-α expression and thereby modulating cardiac remodeling gene programs, including GLUT4 expression critical for cardiomyocyte glucose metabolism. Molecular docking analyses reveal zeaxanthin binds acetylcholinesterase with a calculated free energy of -6.142 kcal/mol and outperforms β-carotene on TTK1 kinase binding (-6.406 vs. -5.962 kcal/mol), suggesting additional neuroprotective and potentially antiproliferative enzymatic interactions. In neuronal tissue, the combined suppression of Aβ accumulation, IL-1β, and iNOS—alongside elevation of monoamine neurotransmitters—points to both inflammatory and synaptic mechanisms underlying the observed cognitive benefits in preclinical aging models.
Clinical Evidence
All available clinical data for zeaxanthin from D. salina derive from rat models of D-galactose-induced pathology, with no registered or published human trials identified in the current literature. The cardiac dysfunction studies (8-week D-galactose induction, 28-day oral treatment at 250 μg/kg zeaxanthin heneicosylate) demonstrated normalization of ECG waveforms, reductions in serum CK-MB and LDH, restoration of SOD, and suppression of NF-κB/iNOS/IL-6 with large apparent effect sizes. The dementia-focused studies showed significant reductions in brain Aβ and neuroinflammatory markers alongside improved spatial memory performance and monoamine restoration after 2-week oral treatment. Confidence in human applicability is low given preclinical-only evidence, small sample sizes, and the known limitations of D-galactose aging models in replicating human pathophysiology; human bioavailability and optimal dosing remain undefined.
Safety & Interactions
In preclinical rat studies, zeaxanthin heneicosylate demonstrated a satisfactory acute safety profile, with no mortality or observable adverse effects at doses up to 1 g/kg in acute oral toxicity testing—approximately 4,000-fold above the effective experimental dose of 250 μg/kg—and no organ toxicity signals observed in sub-chronic treatment groups. Notably, rather than causing hepatorenal side effects, treatment at 250 μg/kg normalized elevated ALT, AST, serum urea, and creatinine in D-galactose-injured rats, suggesting a protective rather than toxic hepatorenal profile at studied doses. No human safety data, drug interaction studies, or toxicology reports in humans are available, representing a critical gap; the compound's high-affinity binding to RAR-α (retinoid receptor alpha) warrants theoretical caution regarding co-administration with synthetic retinoids (isotretinoin, acitretin, bexarotene) due to potential additive or competitive receptor interactions, though this has not been empirically studied. Guidance for use in pregnancy, lactation, pediatric populations, or individuals with chronic hepatic/renal disease cannot be provided based on current evidence, and human clinical use should be considered investigational until adequate Phase I safety trials are conducted.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
Marine zeaxanthinHalophilic microalgae zeaxanthinDunaliella salinaD. salina carotenoid extractZeaxanthin heneicosylateZeaxanthin from Dunaliella salina (Dunaliella salina, marine microalgae)
Frequently Asked Questions
What is zeaxanthin heneicosylate from Dunaliella salina used for?
Zeaxanthin heneicosylate from Dunaliella salina is primarily studied for its cardioprotective and neuroprotective properties in preclinical models. In rat studies, oral doses of 250 μg/kg for 28 days normalized cardiac ECG parameters, reduced inflammatory markers (NF-κB by ~18%, IL-6, iNOS), and restored antioxidant enzyme (SOD) activity in D-galactose-induced cardiac dysfunction, while separate studies showed it reduced brain amyloid-beta and improved cognitive performance in aging models.
Is Dunaliella salina zeaxanthin safe for human consumption?
Preclinical acute oral toxicity studies in rats showed no adverse effects at doses up to 1 g/kg—approximately 4,000 times the effective experimental dose—suggesting a wide safety margin in animal models. However, no human clinical trials or formal toxicology studies in humans have been published, meaning the safety profile for human supplementation has not been established, and its use in humans must be considered investigational at this stage.
How does zeaxanthin from Dunaliella salina differ from synthetic zeaxanthin?
D. salina-derived zeaxanthin is found predominantly in its naturally esterified form (zeaxanthin heneicosylate), which may offer superior gastrointestinal stability and tissue deposition compared to free-form synthetic zeaxanthin, as esterification is associated with improved bioavailability in carotenoid research. The algal matrix also provides co-occurring carotenoids (β-carotene, lutein, astaxanthin) and lipids that may enhance absorption through micellarization, though direct comparative bioavailability studies in humans between D. salina-derived and synthetic zeaxanthin have not been published.
What dose of Dunaliella salina zeaxanthin was used in cardiac studies?
The key cardiac dysfunction study used zeaxanthin heneicosylate at 250 μg/kg body weight orally for 28 days in rats subjected to D-galactose-induced aging (200 mg/kg intraperitoneally for 8 weeks). Applying body surface area allometric scaling, this corresponds to an estimated human equivalent dose of approximately 40 μg/kg (~2,800 μg for a 70 kg adult), but this extrapolation is unvalidated and no human dosing standard has been formally established.
Does Dunaliella salina zeaxanthin help with dementia or brain aging?
In rat models of D-galactose-induced accelerated brain aging, both D. salina whole biomass (250 mg/kg) and isolated zeaxanthin (250 μg/kg) administered orally for 2 weeks significantly reduced escape latency in spatial memory tasks, lowered brain amyloid-beta (Aβ) deposits, decreased neuroinflammatory markers (IL-1β, iNOS), and elevated serotonin, norepinephrine, and dopamine levels. While these results are promising mechanistically, there are no human clinical trials to confirm these effects in people with dementia or age-related cognitive decline, and results from D-galactose rat models do not directly translate to human Alzheimer's disease pathology.
What is the bioavailability difference between zeaxanthin from Dunaliella salina and other natural sources?
Dunaliella salina produces zeaxanthin in a bioavailable form naturally, making it more readily absorbed compared to synthetic alternatives. The microalgae-derived zeaxanthin is often found in esterified forms that may enhance intestinal uptake and tissue distribution. Studies suggest that algae-based sources provide zeaxanthin in lipid-compatible matrices that support better absorption in the gastrointestinal tract compared to isolated synthetic compounds.
What does clinical research show about zeaxanthin from Dunaliella salina for cardiovascular health?
Research in rat models demonstrates that zeaxanthin from Dunaliella salina (at 250 μg/kg orally) can normalize cardiac electrical parameters and reduce markers of heart muscle damage such as CK-MB and LDH levels. The ingredient also appears to lower homocysteine, a cardiovascular risk factor, suggesting potential protective effects against cardiac dysfunction. However, most evidence to date comes from preclinical animal studies, and human clinical trials are needed to confirm these cardiovascular benefits in people.
Who should consider taking zeaxanthin from Dunaliella salina supplementation?
Individuals with concerns about eye health, oxidative stress, or cardiovascular wellness may benefit most from this ingredient, given its antioxidant enzyme-restoring properties. Those seeking natural, microalgae-derived carotenoids rather than synthetic alternatives might find this source particularly relevant. However, consultation with a healthcare provider is recommended to determine if supplementation is appropriate for individual health status and medication regimens.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w zeaxanthin-from-dunaliella-salina-dunaliella-salina-microalgae curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
